

Alex Boussioutas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6276199/publications.pdf>

Version: 2024-02-01

79
papers

7,599
citations

101496

36
h-index

79644

73
g-index

87
all docs

87
docs citations

87
times ranked

12196
citing authors

#	ARTICLE	IF	CITATIONS
1	Cross-validation of survival associated biomarkers in gastric cancer using transcriptomic data of 1,065 patients. <i>Oncotarget</i> , 2016, 7, 49322-49333.	0.8	821
2	A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. <i>Gut</i> , 2012, 61, 673-684.	6.1	562
3	Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline <i>CDH1</i> mutation carriers. <i>Journal of Medical Genetics</i> , 2015, 52, 361-374.	1.5	479
4	Identification of Molecular Subtypes of Gastric Cancer With Different Responses to PI3-Kinase Inhibitors and 5-Fluorouracil. <i>Gastroenterology</i> , 2013, 145, 554-565.	0.6	381
5	Oncogenic Pathway Combinations Predict Clinical Prognosis in Gastric Cancer. <i>PLoS Genetics</i> , 2009, 5, e1000676.	1.5	354
6	Interleukin-11 Is the Dominant IL-6 Family Cytokine during Gastrointestinal Tumorigenesis and Can Be Targeted Therapeutically. <i>Cancer Cell</i> , 2013, 24, 257-271.	7.7	341
7	Intrinsic Subtypes of Gastric Cancer, Based on Gene Expression Pattern, Predict Survival and Respond Differently to Chemotherapy. <i>Gastroenterology</i> , 2011, 141, 476-485.e11.	0.6	304
8	Hyperactivation of Stat3 in gp130 mutant mice promotes gastric hyperproliferation and desensitizes TGF- β signaling. <i>Nature Medicine</i> , 2005, 11, 845-852.	15.2	284
9	Acceptability and accuracy of a non-endoscopic screening test for Barrett's oesophagus in primary care: cohort study. <i>BMJ: British Medical Journal</i> , 2010, 341, c4372-c4372.	2.4	271
10	Hereditary diffuse gastric cancer: updated clinical practice guidelines. <i>Lancet Oncology</i> , The, 2020, 21, e386-e397.	5.1	237
11	Macrophage spatial heterogeneity in gastric cancer defined by multiplex immunohistochemistry. <i>Nature Communications</i> , 2019, 10, 3928.	5.8	210
12	Cancer Risks for <i>MLH1</i> and <i>MSH2</i> Mutation Carriers. <i>Human Mutation</i> , 2013, 34, 490-497.	1.1	201
13	Point Mutations in Exon 1B of APC Reveal Gastric Adenocarcinoma and Proximal Polyposis of the Stomach as a Familial Adenomatous Polyposis Variant. <i>American Journal of Human Genetics</i> , 2016, 98, 830-842.	2.6	201
14	Signatures of tumour immunity distinguish Asian and non-Asian gastric adenocarcinomas. <i>Gut</i> , 2015, 64, 1721-1731.	6.1	197
15	TOPGEAR: A Randomized, Phase III Trial of Perioperative ECF Chemotherapy with or Without Preoperative Chemoradiation for Resectable Gastric Cancer: Interim Results from an International, Intergroup Trial of the AGITG, TROG, EORTC and CCTG. <i>Annals of Surgical Oncology</i> , 2017, 24, 2252-2258.	0.7	186
16	Risk of Colorectal Cancer for Carriers of Mutations in <i>MUTYH</i> , With and Without a Family History of Cancer. <i>Gastroenterology</i> , 2014, 146, 1208-1211.e5.	0.6	180
17	Distinctive patterns of gene expression in premalignant gastric mucosa and gastric cancer. <i>Cancer Research</i> , 2003, 63, 2569-77.	0.4	172
18	TOPGEAR: a randomised phase III trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer (an international,)	Tj ETQq0 0 0rgBT /Overlock 10 Tf	

#	ARTICLE	IF	CITATIONS
19	Comprehensive genomic meta-analysis identifies intra-tumoural stroma as a predictor of survival in patients with gastric cancer. <i>Gut</i> , 2013, 62, 1100-1111.	6.1	139
20	IL-33-mediated mast cell activation promotes gastric cancer through macrophage mobilization. <i>Nature Communications</i> , 2019, 10, 2735.	5.8	139
21	Risk of Metachronous Colon Cancer Following Surgery for Rectal Cancer in Mismatch Repair Gene Mutation Carriers. <i>Annals of Surgical Oncology</i> , 2013, 20, 1829-1836.	0.7	103
22	The challenges of gene expression microarrays for the study of human cancer. <i>Cancer Cell</i> , 2006, 9, 333-339.	7.7	97
23	Novel regions of chromosomal amplification at 6p21, 5p13, and 12q14 in gastric cancer identified by array comparative genomic hybridization. <i>Genes Chromosomes and Cancer</i> , 2005, 42, 247-259.	1.5	90
24	mTORC1 inhibition restricts inflammation-associated gastrointestinal tumorigenesis in mice. <i>Journal of Clinical Investigation</i> , 2013, 123, 767-81.	3.9	89
25	Processed pseudogenes acquired somatically during cancer development. <i>Nature Communications</i> , 2014, 5, 3644.	5.8	86
26	Intestinal metaplasia: A premalignant lesion involved in gastric carcinogenesis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2009, 24, 193-201.	1.4	84
27	Topological and Functional Discovery in a Gene Coexpression Meta-Network of Gastric Cancer. <i>Cancer Research</i> , 2006, 66, 232-241.	0.4	83
28	The Interleukin-6 Family Cytokine Interleukin-11 Regulates Homeostatic Epithelial Cell Turnover and Promotes Gastric Tumor Development. <i>Gastroenterology</i> , 2009, 136, 967-977.e3.	0.6	79
29	Role of p53 in the progression of gastric cancer. <i>Oncotarget</i> , 2014, 5, 12016-12026.	0.8	64
30	A Signature Predicting Poor Prognosis in Gastric and Ovarian Cancer Represents a Coordinated Macrophage and Stromal Response. <i>Clinical Cancer Research</i> , 2014, 20, 2761-2772.	3.2	60
31	Second harmonic generation imaging via nonlinear endomicroscopy. <i>Optics Express</i> , 2010, 18, 1255.	1.7	57
32	Safety and Acceptability of Esophageal Cytosponge Cell Collection Device in a Pooled Analysis of Data From Individual Patients. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 647-656.e1.	2.4	54
33	Tumor testing to identify lynch syndrome in two Australian colorectal cancer cohorts. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 427-438.	1.4	47
34	Identification and validation of novel candidate protein biomarkers for the detection of human gastric cancer. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2014, 1844, 1051-1058.	1.1	45
35	Screening participation for people at increased risk of colorectal cancer due to family history: a systematic review and meta-analysis. <i>Familial Cancer</i> , 2013, 12, 459-472.	0.9	42
36	Quantification and Characterization of Mucosa-Associated and Intracellular <i>Escherichia coli</i> in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 2326-2338.	0.9	40

#	ARTICLE	IF	CITATIONS
37	Role of tumour molecular and pathology features to estimate colorectal cancer risk for first-degree relatives. <i>Gut</i> , 2015, 64, 101-110.	6.1	40
38	Imaging of goblet cells as a marker for intestinal metaplasia of the stomach by one-photon and two-photon fluorescence endomicroscopy. <i>Journal of Biomedical Optics</i> , 2009, 14, 064031.	1.4	35
39	Revised Australian national guidelines for colorectal cancer screening: family history. <i>Medical Journal of Australia</i> , 2018, 209, 455-460.	0.8	35
40	Screening Participation Predictors for People at Familial Risk of Colorectal Cancer. <i>American Journal of Preventive Medicine</i> , 2013, 44, 496-506.	1.6	34
41	Immunological battlefield in gastric cancer and role of immunotherapies. <i>World Journal of Gastroenterology</i> , 2016, 22, 6373.	1.4	33
42	Germline mutations in <i>PMS2</i> and <i>MLH1</i> in individuals with solitary loss of PMS2 expression in colorectal carcinomas from the Colon Cancer Family Registry Cohort. <i>BMJ Open</i> , 2016, 6, e010293.	0.8	33
43	An orthotopic mouse model of gastric cancer invasion and metastasis. <i>Scientific Reports</i> , 2018, 8, 825.	1.6	33
44	Risk factors for metachronous colorectal cancer following a primary colorectal cancer: A prospective cohort study. <i>International Journal of Cancer</i> , 2016, 139, 1081-1090.	2.3	32
45	Are the common genetic variants associated with colorectal cancer risk for DNA mismatch repair gene mutation carriers?. <i>European Journal of Cancer</i> , 2013, 49, 1578-1587.	1.3	31
46	The unfolded protein response is activated in Helicobacter-induced gastric carcinogenesis in a non-cell autonomous manner. <i>Laboratory Investigation</i> , 2013, 93, 112-122.	1.7	31
47	Multivitamin, calcium and folic acid supplements and the risk of colorectal cancer in Lynch syndrome. <i>International Journal of Epidemiology</i> , 2016, 45, 940-953.	0.9	27
48	2D-DIGE analysis of sera from transgenic mouse models reveals novel candidate protein biomarkers for human gastric cancer. <i>Journal of Proteomics</i> , 2012, 77, 40-58.	1.2	26
49	Screening Practices of Unaffected People at Familial Risk of Colorectal Cancer. <i>Cancer Prevention Research</i> , 2012, 5, 240-247.	0.7	25
50	Cost-effectiveness of family history-based colorectal cancer screening in Australia. <i>BMC Cancer</i> , 2014, 14, 261.	1.1	24
51	Cell graph neural networks enable the precise prediction of patient survival in gastric cancer. <i>Npj Precision Oncology</i> , 2022, 6, .	2.3	22
52	High-dimensional analyses reveal a distinct role of T cell subsets in the immune microenvironment of gastric cancer. <i>Clinical and Translational Immunology</i> , 2020, 9, e1127.	1.7	21
53	Down-regulation of a pro-apoptotic pathway regulated by PCAF/ADA3 in early stage gastric cancer. <i>Cell Death and Disease</i> , 2018, 9, 442.	2.7	20
54	Early relapses after adjuvant chemotherapy suggests primary chemoresistance in diffuse gastric cancer. <i>PLoS ONE</i> , 2017, 12, e0183891.	1.1	19

#	ARTICLE	IF	CITATIONS
55	Screening practices of Australian men and women categorized as "at or slightly above average risk" of colorectal cancer. <i>Cancer Causes and Control</i> , 2012, 23, 1853-1864.	0.8	17
56	Toward transmural healing: Sonographic healing is associated with improved long-term outcomes in patients with Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 56, 84-94.	1.9	17
57	A cohort study and meta-analysis of the evidence for consideration of Lauren subtype when prescribing adjuvant or palliative chemotherapy for gastric cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592093035.	1.4	14
58	SFRP4 drives invasion in gastric cancer and is an early predictor of recurrence. <i>Gastric Cancer</i> , 2021, 24, 589-601.	2.7	12
59	Lamina propria macrophage phenotypes in relation to Escherichia coli in Crohn's disease. <i>BMC Gastroenterology</i> , 2015, 15, 75.	0.8	11
60	Rapid Resistance of FGFR-driven Gastric Cancers to Regorafenib and Targeted FGFR Inhibitors can be Overcome by Parallel Inhibition of MEK. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 704-715.	1.9	10
61	"Why don't I need a colonoscopy?" A novel approach to communicating risks and benefits of colorectal cancer screening. , 2018, 47, 343-349.		9
62	Diet and risk of gastro-oesophageal reflux disease in the Melbourne Collaborative Cohort Study. <i>Public Health Nutrition</i> , 2021, 24, 5034-5046.	1.1	8
63	The Role of Innate Immune Cells in Tumor Invasion and Metastasis. <i>Cancers</i> , 2021, 13, 5885.	1.7	8
64	Spot Diagnosis. <i>New England Journal of Medicine</i> , 2014, 370, 2229-2236.	18.9	7
65	Predictors of outcome after surgery for gastric cancer in a Western cohort. <i>ANZ Journal of Surgery</i> , 2016, 86, 469-474.	0.3	6
66	Family history-based colorectal cancer screening in Australia: A modelling study of the costs, benefits, and harms of different participation scenarios. <i>PLoS Medicine</i> , 2018, 15, e1002630.	3.9	6
67	A systematic review of risk-reducing cancer surgery outcomes for hereditary cancer syndromes. <i>European Journal of Surgical Oncology</i> , 2019, 45, 2241-2250.	0.5	5
68	Young people's experiences of a CDH1 pathogenic variant: Decision-making about gastric cancer risk management. <i>Journal of Genetic Counseling</i> , 2021, , .	0.9	5
69	CD10 and Das1: a biomarker study using immunohistochemistry to subtype gastric intestinal metaplasia. <i>BMC Gastroenterology</i> , 2022, 22, 197.	0.8	5
70	DEMoS: a deep learning-based ensemble approach for predicting the molecular subtypes of gastric adenocarcinomas from histopathological images. <i>Bioinformatics</i> , 2022, 38, 4206-4213.	1.8	5
71	A bi-ordering approach to linking gene expression with clinical annotations in gastric cancer. <i>BMC Bioinformatics</i> , 2010, 11, 477.	1.2	3
72	Mechanisms for the Sex-Specific Effect of <i>H. Pylori</i> on Risk of Gastroesophageal Reflux Disease and Barrett's Esophagus. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 1630-1637.	1.1	2

#	ARTICLE	IF	CITATIONS
73	Gastric involvement of plasmacytoma associated with t(4:14) and chromosome 13 deletion. <i>Leukemia and Lymphoma</i> , 2006, 47, 1973-1975.	0.6	1
74	GASTROINTESTINAL ABNORMALITIES IDENTIFIED BY FLUORESCENCE ENDOMICROSCOPY. <i>Journal of Innovative Optical Health Sciences</i> , 2012, 05, 1250026.	0.5	1
75	Pathophysiology of Hereditary Diffuse Gastric Cancer. , 2015, , 91-109.		1
76	Premalignant lesions of the stomach and management of early neoplastic lesions. , 2021, , 185-216.		0
77	Genomic and Proteomic Advances in Gastric Cancer. , 2009, , 285-321.		0
78	Contribution of the -Omics Era to Our Understanding of Preinvasive Disease and Progression to Cancer. , 2011, , 77-110.		0
79	Differential response to adjuvant chemotherapy based on Lauren subtype affects clinical outcome of gastric cancer: A cohort study and meta-analysis.. <i>Journal of Clinical Oncology</i> , 2018, 36, 4048-4048.	0.8	0